Allergan, Inc. Announces Appointment of Douglas S. Ingram as President
News Jun 25, 2013
Allergan, Inc. announced that David E.I. Pyott, Chairman of the Board and Chief Executive Officer, Allergan, and the Allegan Board of Directors have named Douglas S. Ingram as President of Allergan. In this newly established role, Mr. Ingram will report directly to Mr. Pyott and will lead the company’s global commercial operations, with responsibility for the company’s broad portfolio of pharmaceutical, consumer and medical device products including leading Ophthalmology products such as RESTASIS®, LUMIGAN®, ALPHAGAN®, COMBIGAN®, GANFORT®, OPTIVE® and OZURDEX®; Facial Aesthetics products such as BOTOX® Cosmetic and the JUVÉDERM® family of facial fillers; BOTOX® for therapeutic uses, approved in over 85 countries to treat 26 different conditions such as spasticities, dystonias, chronic migraine and the urological conditions of neurogenic detrusor overactivity and idiopathic overactive bladder; and Medical Dermatology products such as ACZONE®. Mr. Ingram will begin transitioning to this new role immediately.
“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” said David E.I. Pyott, Chairman of the Board and Chief Executive Officer, Allergan. “Doug has built an impressive record of accomplishment and is widely regarded throughout our organization as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”
With more than 25 years of professional experience, Mr. Ingram has a strong background in the health care industry, both in the U.S. and internationally. For the past three years, Mr. Ingram has served as Executive Vice President and President, Europe, Africa and Middle East (EAME). In this role, he was responsible for Allergan’s regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development and general management.
Prior to leading the EAME region, Mr. Ingram served as Executive Vice President and Chief Administrative Officer. During Mr. Ingram’s tenure in this role, at various times, he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr. Ingram also served as Allergan’s Secretary and Chief Ethics Officer from July 2001 to July 2010. Mr. Ingram joined Allergan in 1996 as Senior Attorney and Chief Litigation Officer and was promoted to Associate General Counsel and Assistant Secretary, and later, to General Counsel.
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018